Search
Rusfertide
go.drugbank.com/drugs/DB17724ApprovedInvestigationalRusfertide is a hepcidin mimetic used to treat erythrocytosis in adults with polycythemia vera. … [L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer.
CSL-689
go.drugbank.com/drugs/DB17726InvestigationalCSL689 is a recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP).
RLYB212
go.drugbank.com/drugs/DB17727InvestigationalRLYB212 is a human monoclonal antibody against Antigen-1A Immunoglobulin (HPA-1A). It is currently being developed by Rallybio for the prevention of fetal and neonatal alloimmune thrombocytopenia.
MBP-091
go.drugbank.com/drugs/DB17741ExperimentalMBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) caused by infection with Marburg virus (MARV).[L46212]
Navepegritide
go.drugbank.com/drugs/DB17824ApprovedInvestigational[L56058,A275435] Navepegritide is a prodrug of active C-type natriuretic peptide (CNP) consisting of a CNP moiety transiently conjugated to two methoxy polyethylene glycol (mPEG) moieties via a proprietary … Achondroplasia, the most prevalent skeletal dysplasia, is caused by a gain-of-function variant in the fibroblast growth factor receptor 3 (FGFR3), which leads to overactive downstream signaling that inhibits
SIG-001
go.drugbank.com/drugs/DB17826InvestigationalSIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer
VaxSyn
go.drugbank.com/drugs/DB17827InvestigationalVaxSyn HIV-1 is a recombinant form of the HIV envelope protein gp 160 developed by MicroGeneSys and the National Institute of Allergy and Infectious Diseases (NIAID).
DS-1211
go.drugbank.com/drugs/DB17837InvestigationalDS-1211 is a potent and selective novel small molecule tissue-nonspecific alkaline phosphatase (TNAP) inhibitor.[A259786]
Synonyms: Ac-D-Leu-OHSAR-439459
go.drugbank.com/drugs/DB17864InvestigationalSAR-439459 is a pan-transforming Growth Factor-beta (TGFβ) neutralizing antibody.[A259862] Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.
Synonyms: MAB HUMAN (IGG4) ANTI P01137 (TGFB1_HUMAN) OR ANTI P61812 (TFGB2_HUMAN) OR ANTI P10600 (TGFB3_HUMAN)(SAR439459)QRX-411
go.drugbank.com/drugs/DB17868ExperimentalQRX-411 is a first-in-class RNA-based oligonucleotide designed to restore wild-type USH2A mRNA, leading to the production of the functional USH2A protein.